It's easy to extrapolate the current ideas in fintech (and the venture capital) to healthcare. This write up in Financial Times relates to a state-owned fund for businesses. I have highlighted something specific in the context of public funding of the "scientific experiments" and consequently healthcare. The UK government’s venture fund has a problem — … Continue reading Should the public pay for risky ventures? →